Disease Site‐Specific Outcomes in p 16‐Positive Non‐Oropharyngeal Mucosal Head and Neck Cancer
Head & Neck · 2026-08 · 48 (8) · 2156-2169
DOI: 10.1002/hed.70230 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, online erschienen am 12.03.2026. Verfasst von Revadhi C Chelvarajah und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, the Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck, Cyclin-Dependent Kinase Inhibitor p16. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objectives
To report disease‐free survival (DFS) in p16‐positive non‐oropharyngeal head‐and‐neck squamous‐cell carcinoma (HNSCC).
Methods
Curatively‐treated non‐oropharyngeal HNSCC (2009–2021) were reviewed. DFS was compared among p16‐positive, p16‐negative, and p16‐untested cases for the overall cohort and by disease site. Multivariable analysis estimated adjusted hazard ratio (aHR) for p16‐positivity.
Results
Among 3061 non‐oropharyngeal HNSCC, 91 p16+, 375 p16−, 2595 untested; median follow‐up 4.7 years. P16‐positive patients had superior 5‐year DFS versus p16−/untested (74% vs. 48%/59%; aHR 0.40 [0.26–0.61], p < 0.001). This advantage was evident in the larynx (86% vs. 52%/63%; aHR 0.26 [0.09–0.71], p = 0.005), hypopharynx (70% vs. 25%/37%; aHR 0.55 [0.10–0.50], p < 0.001), and nasal cavity (82% vs. 38%/66%; aHR 0.31 [0.11–0.88], p = 0.028). No significant DFS differences were seen in paranasal sinus (40% vs. 64%/41%; p = 0.39) or oral cavity (50% vs. 57%/58%; p = 0.94). Conclusion p16‐positivity confers a DFS benefit in larynx/hypopharynx/nasal cavity, but not in paranasal sinus or oral SCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, the Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
- Department of Biostatistics, the Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
- Department of Otolaryngology-Head & Neck Surgery, the Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
- Division of Medical Oncology, the Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
- Department of Laboratory Medicine & Pathobiology, the Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
ORCID-Profile: Christopher M K L Yao, Stephen M Smith, Chiaojung Jillian Tsai, John de Almeida, Shao Hui Huang
Zitieren
APA
Chelvarajah, R. C., Chee, L. Y. S., Su, J., O'Sullivan, B., Yao, C. M. K. L., Sanz-Garcia, E., Smith, S. M., Weinreb, I., Bratman, S., Cho, B. C. J., Hahn, E., Hope, A., Hosni, A., Kim, J., McPartlin, A., Malik, N., Tsai, C. J., de Almeida, J., Spreafico, A., …, & Waldron, J. N. (2026). Disease Site‐Specific Outcomes in p 16‐Positive Non‐Oropharyngeal Mucosal Head and Neck Cancer. Head & Neck, 48(8), 2156-2169. https://doi.org/10.1002/hed.70230
Vancouver
Chelvarajah RC, Chee LYS, Su J, O'Sullivan B, Yao CMKL, Sanz-Garcia E, et al. Disease Site‐Specific Outcomes in p 16‐Positive Non‐Oropharyngeal Mucosal Head and Neck Cancer. Head & Neck. 2026;48(8):2156-2169. doi:10.1002/hed.70230
BibTeX
@article{Chelvarajah2026,
author = {Chelvarajah, Revadhi C and Chee, Lessandra Y S and Su, Jie and O'Sullivan, Brian and Yao, Christopher M K L and Sanz-Garcia, Enrique and Smith, Stephen M and Weinreb, Ilan and Bratman, Scott and Cho, B C John and Hahn, Ezra and Hope, Andrew and Hosni, Ali and Kim, John and McPartlin, Andrew and Malik, Nauman and Tsai, Chiaojung Jillian and de Almeida, John and Spreafico, Anna and Tong, Li and Huang, Shao Hui and Waldron, John N},
title = {Disease Site‐Specific Outcomes in p 16‐Positive Non‐Oropharyngeal Mucosal Head and Neck Cancer},
journal = {Head & Neck},
year = {2026},
volume = {48},
number = {8},
pages = {2156--2169},
doi = {10.1002/hed.70230}
}
EUVIMED